Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation

American Journal of Hematology

Volumn 88, Issue 7, 2013, Pages 550-555

  Liu, Qifa ^a   Xuan, Li ^a   Liu, Hui ^a   Huang, Fen ^a   Zhou, Hongsheng ^a   Fan, Zhiping ^a   Zhao, Ke ^a   Wu, Meiqing ^a   Xu, Lanping ^b   Zhai, Xiao ^a   Zhang, Fuhua ^a   Liu, Can ^a   Sun, Jing ^a   Huang, Xiaojun ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; FOSCARNET; GANCICLOVIR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY; VINCRISTINE;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; B LYMPHOCYTE; CHILD; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG EFFICACY; ENCEPHALITIS; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; FEVER; FOLLOW UP; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MYELITIS; PATIENT MONITORING; PNEUMONIA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SCHOOL CHILD; VIREMIA; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIVIRAL AGENTS; B-LYMPHOCYTES; CHILD; DNA, VIRAL; DRUG MONITORING; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 84879352932     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23452     Document Type: Article

References (39)

1. Mato AR, Morgans A, Luger SM. Novel strategies for relapsed and refractory acute myeloid leukemia. Curr Opin Hematol 2008;15:108-114.
2. Kim SY, Lee DG, Kim MS, et al. The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease. Am J Hematol 2008;83:784-788.
3. Lv M, Huang X. Allogeneic hematopoietic stem cell transplantation in China: Where we are and where to go. J Hematol Oncol 2012;5:10.
4. Hill GR, Krenger W, Ferrara JL. The role of cytokines in acute graft-versus-host disease. Cytokines Cell Mol Ther 1997;3:257-266.
5. Hossain MS, Roback JD, Pollack BP, et al. Chronic GvHD decreases antiviral immune responses in allogeneic BMT. Blood 2007;109:4548-4556.
6. Bitan M. Epstein-Barr virus infection after stem cell transplantation: New concepts are needed both for the donor and the recipient. Clin Infect Dis 2006;43:896-897.
7. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001;98:972-978.
8. Buadi FK, Heyman MR, Gocke CD, et al. Treatment and outcomes of post-transplant lymphoproliferative disease: A single institution study. Am J Hematol 2007;82:208-214.
9. Kinch A, Oberg G, Arvidson J, et al. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis 2007;39:235-244.
10. Behr J, Schaefer M, Littmann E, et al. Psychiatric symptoms and cognitive dysfunction caused by Epstein-Barr virus-induced encephalitis. Eur Psychiatry 2006;21:521-522.
11. Liu QF, Fan ZP, Luo XD, et al. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation. Transpl Infect Dis 2010;12:284-291.
12. Wu XL, Liu QF. Epstein-Barr virus-associated Diseases in Allogeneic Hematopoietic Stem Cell Transplantation. J Hematol Oncol 2012; 5:A8.
13. Xuan L, Huang F, Fan Z, et al. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. J Hematol Oncol 2012;5:46.
14. Styczynski J, Einsele H, Gil L, et al. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: A comprehensive review of reported cases. Transpl Infect Dis 2009;11:383-392.
15. Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: Guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009;43:757-770.
16. Ahmad I, Cau NV, Kwan J, et al. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation. Transplantation 2009;87:1240-1245.
17. Cesaro S, Pegoraro A, Tridello G, et al. A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation. Transplantation 2010;89:1533-1540.
18. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2011;115:925-935.
19. Reddy N, Rezvani K, Barrett AJ, et al. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant 2011;17:591-597.
20. Merlo A, Turrini R, Dolcetti R, et al. The interplay between Epstein-Barr virus and the immune system: A rationale for adoptive cell therapy of EBV-related disorders. Haematologica 2010;95:1769-1777.
21. Yancoski J, Danielian S, Ibanez J, et al. Quantification of Epstein-Barr virus load in Argentinean transplant recipients using real-time PCR. J Clin Virol 2004;31:58-65.
22. Hoshino Y, Kimura H, Tanaka N, et al. Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation. Br J Haematol 2001;115:105-111.
23. Aalto SM, Juvonen E, Tarkkanen J, et al. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. Clin Infect Dis 2007;45:1305-1309.
24. Gartner BC, Schafer H, Marggraff K, et al. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol 2002;40:351-358.
25. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002;99:4364-4369.
26. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006;107:3053-3057.
27. Ram R, Ben-Bassat I, Shpilberg O, et al. The late adverse events of rituximab therapy-rare but there! Leuk Lymphoma 2009;50:1083-1095.
28. Buser A, Stern M, Arber C, et al. Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: An effect of pretreatment with rituximab? Bone Marrow Transplant 2008;42:483-487.
29. Corti P, Peters C, Balduzzi A, et al. Reconstitution of lymphocyte subpopulations in children with inherited metabolic storage diseases after haematopoietic cell transplantation. Br J Haematol 2005;130:249-255.
30. Gottschalk S, Ng CY, Perez M, et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001;97:835-843.
31. Chen H, Liu KY, Xu LP, et al. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. J Hematol Oncol 2012;5:29.
32. Wagner HJ, Rooney CM, Heslop HE. Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002;8:1-8.
33. Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Post-Transplant Lymphoproliferative Disorders. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008. pp. 343-349.
34. Juvonen E, Aalto S, Tarkkanen J, et al. Retrospective evaluation of serum Epstein Barr virus DNA levels in 406 allogeneic stem cell transplant patients. Haematologica 2007;92:819-825.
35. Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009;113:4992-5001.
36. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999;94:2208-2216.
37. Omar H, Hagglund H, Gustafsson-Jernberg A, et al. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transpl Infect Dis 2009;11:393-399.
38. Hou HA, Yao M, Tang JL, et al. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute. Bone Marrow Transplant 2009;43:315-321.
39. Di Nardo CD, Tsai DE. Treatment advances in posttransplant lymphoproliferative disease. Curr Opin Hematol 2010;17:368-374.